Nauman Shahid, MD
Nephrology · Greenville, NCNPI 1225298490
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,020 of the $5,518 with a category attached, or 72.8%. Aurinia Pharma U.S., Inc. accounts for 85.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $4,845 and has fallen 97.6% since, to $118 in 2025.
Across 49 payments — averaging $112.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$5K
- Amgen$234
- AstraZeneca$174
- GSK$88
- Vifor Pharma, Inc.$37
- Akebia Therapeutics Inc$36
- plus $234 from 12 others
Across 533 payments — averaging $3698.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.1M
- Vertex$522K
- Akebia Therapeutics Inc$192K
- Bayer$120K
- Eli Lilly$14K
- Gilead$9K
What the payments were for
- Speaking & faculty fees$4,02073%
- Travel & lodging$65212%
- Food & beverage$84715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 5 | $4,715 |
| Amgen(2 entities) | 14 | $234 |
| AstraZeneca(2 entities) | 6 | $174 |
| GSK | 5 | $88 |
| Vifor Pharma, Inc. | 3 | $37 |
| Akebia Therapeutics Inc | 2 | $36 |
| OPKO Pharmaceuticals, LLC | 2 | $29 |
| Bayer | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$4,658
How this compares
$5,518 in reported general payments places this provider in the 80th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 56 | $61,412 |
| VelphoroSucroferric Oxyhydroxide | 15 | $45,595 |
| JardianceEmpagliflozin | 24 | $24,673 |
| OzempicSemaglutide | 20 | $18,922 |
| EliquisApixaban | 18 | $11,525 |
| Bumetanide | 65 | $4,734 |
| Clonidine | 21 | $3,814 |
| Sevelamer Carbonate | 35 | $3,135 |
| Cinacalcet Hcl | 25 | $2,253 |
| Valsartan | 78 | $2,071 |
| Tamsulosin Hcl | 53 | $1,493 |
| Calcium Acetate | 13 | $1,364 |
| Hydralazine Hcl | 42 | $1,059 |
| Famotidine | 34 | $766 |
| Amlodipine Besylate | 110 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $174 | $61,41256 claims |
| Fresenius USA Marketing, Inc.Velphoro | $15 | $45,59515 claims |
| Boehringer IngelheimJardiance | $14 | $24,67324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Greenville
- William KendrickGreenville$125K
- Richard BlairGreenville$13K
- Anthony ProvenzanoGreenville$11K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.